2don MSN
FDA's Marty Makary: Everything should be over-the-counter unless it's unsafe or requires monitoring
FDA's Marty Makary sits down with CNBC's Annika Kim Constantino to discuss the vaccine regulatory environment, compounding ...
Makary said the FDA is looking at prescription drugs like nausea medications and vaginal estrogen, and hopes to make changes ...
The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals ...
A system that allows drug makers to profit from restricted access will never liberalize on its own—and patients will continue ...
The FDA plans to adopt a new policy that will do away with the default requirement to base regulatory filings for new medicines on two pivotal trials, according to Commissioner Marty Makary.
Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug applications process ...
FDA head Marty Makary explains why agency is pulling safety warnings for menopause hormone therapies
The Food and Drug Administration has approved removing safety warnings from several menopausal hormone therapy products. FDA ...
In a NEJM article, Commissioner Martin Makary and top deputy Vinay Prasad argued that the new policy should lower development costs and speed development without compromising agency standards.
FDA Commissioner Marty Makary says he believes "everything should be over the counter" unless a drug is unsafe, addictive or ...
Drug sponsors should nevertheless bolster their application with “confirmative evidence,” chief regulators Marty Makary and Vinay Prasad said on Wednesday, including mechanistic data or findings from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results